Abstract:The Raf-MEK-ERK pathway is commonly activated in human cancers, largely attributable to the extracellular signal-regulated kinases (ERKs) being a common downstream target of growth factor receptors, Ras, and Raf. Elevation of these up-stream signals occurs frequently in a variety of malignancies and ERK kinases play critical roles in promoting cell proliferation. Therefore, inhibition of MEK-mediated ERK activation is very appealing in cancer therapy. Consequently, numerous MEK inhibitors have been developed over the years. However, clinical trials have yet to produce overwhelming support for using MEK inhibitors in cancer therapy. Although complex reasons may have contributed to this outcome, an alternative possibility is that the MEK-ERK pathway may not solely provide proliferation signals to malignancies, the central scientific rationale in developing MEK inhibitors for cancer therapy. Recent developments may support this alternative possibility. Accumulating evidence now demonstrated that the MEK-ERK pathway contributes to the proper execution of cellular DNA damage response (DDR), a major pathway of tumor suppression. During DDR, the MEK-ERK pathway is commonly activated, which facilitates the proper activation of DDR checkpoints to prevent cell division. Inhibition of MEK-mediated ERK activation, therefore, compromises checkpoint activation. As a result, cells may continue to proliferate in the presence of DNA lesions, leading to the accumulation of mutations and thereby promoting tumorigenesis. Alternatively, reduction in checkpoint activation may prevent efficient repair of DNA damages, which may cause apoptosis or cell catastrophe, thereby enhancing chemotherapy's efficacy. This review summarizes our current understanding of the participation of the ERK kinases in DDR.

Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

MAPK/JNK Signalling: a Potential Autophagy Regulation Pathway

Understanding MAPK Signaling Pathways in Apoptosis

MAPK/JNK signaling: A potential autophagy regulation pathway.

ERK1/2 MAP Kinases in Cell Survival and Apoptosis

Role of Phosphatidylinositol 3-Kinase and Specific Protein Kinase B Isoforms in the Suppression of Apoptosis Mediated by the Abelson Protein-tyrosine Kinase

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

ERK/MAPK signalling pathway and tumorigenesis

ERK/MAPK Signalling Pathway and Tumorigenesis (Review)

ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer

Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases

Signaling pathways mediating anti-apoptotic action of neurotrophins

p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents.

C-Jun N-Terminal Kinase Enhances Mst1-Mediated Pro-Apoptotic Signaling Through Phosphorylation At Serine 82

Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis

The MAPK pathway across different malignancies: A new perspective

Role of Mitogen‐activated Protein Kinases in Activation‐induced Apoptosis of T Cells

MAP kinase pathway signalling is essential for extracellular matrix determined mammary epithelial cell survival

Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy

ERK signalling: a master regulator of cell behaviour, life and fate